Gadoterate meglumine
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Hepatocellular Carcinoma
Conditions
Hepatocellular Carcinoma
Trial Timeline
May 9, 2013 → Oct 12, 2015
NCT ID
NCT01806740About Gadoterate meglumine
Gadoterate meglumine is a approved stage product being developed by Guerbet for Hepatocellular Carcinoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT01806740. Target conditions include Hepatocellular Carcinoma.
What happened to similar drugs?
4 of 20 similar drugs in Hepatocellular Carcinoma were approved
Approved (4) Terminated (1) Active (15)
Hype Score Breakdown
Clinical
20
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01806740 | Approved | Terminated |
Competing Products
20 competing products in Hepatocellular Carcinoma